Macrocyclic peptides are a promising chemotype for drug discovery, given their attractive properties of proteolytic stability, bioavailability and the ability to inhibit protein-protein interactions. Approaches to the generation of macrocyclic peptides include optimisation of hits from library screening
de novo design from known ligands and antibody paratopes or protein-protein interactions
constraint of linear peptides to afford beneficial properties of macrocycles
and novel approaches to cyclisation. We describe the recent literature and exemplify these approaches in the design of peptide macrocycles, and the benefits of incorporating computational and structure-guided approaches into compound design and optimisation. The benefits of the use of structural biology as a component part of phage display campaigns are further exemplified by reference to the optimisation of Bicycle® molecules.